Literature DB >> 20700802

Pars plana vitrectomy with and without triamcinolone acetonide assistance in pseudophakic retinal detachment complicated with proliferative vitreoretinopathy.

Nur Acar1, Ziya Kapran, Tugrul Altan, Yaprak Banu Unver, Ercan Pasaoglu.   

Abstract

PURPOSE: To evaluate the anatomical and functional outcomes of pars plana vitrectomy (PPV) in pseudophakic retinal detachment (RD) complicated with proliferative vitreoretinopathy (PVR) without previous scleral buckling (SB) or vitrectomy, both with and without triamcinolone acetonide (TA) assistance.
METHODS: In this retrospective, interventional, comparative case series, 72 pseudophakic eyes with RD with PVR grade C1 or greater underwent PPV either with (group 1, n = 40) or without (group 2, n = 32) TA assistance. Eyes with a minimum of 6 months of follow-up were evaluated. Main outcome measures were reattachment, redetachment, complication rate, and changes in visual acuity (VA).
RESULTS: The mean follow-up period was 14.57 +/- 8.55 months. Single-surgery and final reattachment rates were 87.50% and 95% in group 1, and 78.12 % and 96.87% in group 2, (P = 0.349, P = 1.000). Redetachment rates were 12.50% in group 1 and 21.87% group 2 (P = 0.349). In both groups the mean VA increased significantly in postoperative week 1 and in all control visits (P< 0.001) with no difference in complication rate (P > 0.05).
CONCLUSIONS: In this study PPV with TA assistance resulted in a lower, albeit statistically insignificant, redetachment rate in the treatment of RD complicated with PVR compared to PPV without TA assistance in eyes without previous SB or PPV. Visual acuity improved in 72% of eyes in both groups. Intraoperative and postoperative complication rates were also similar.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20700802     DOI: 10.1007/s10384-010-0807-z

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  23 in total

1.  Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy.

Authors:  Keita Yamakiri; Taiji Sakamoto; Yoshihiro Noda; Masaaki Nakahara; Nobuchika Ogino; Toshiaki Kubota; Mitsunobu Yokoyama; Mariko Furukawa; Yasushi Sonoda; Tomomi Yamada; Norihito Doi; Hiroshi Enaida; Yasuaki Hata; Tatsuro Ishibashi
Journal:  Ophthalmology       Date:  2007-02       Impact factor: 12.079

2.  Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations.

Authors:  T Hida; D Chandler; J E Arena; R Machemer
Journal:  Am J Ophthalmol       Date:  1986-02-15       Impact factor: 5.258

3.  Proliferative vitreoretinopathy. The Silicone Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1985-05-15       Impact factor: 5.258

4.  Vitrectomy with silicone oil or long-acting gas in eyes with severe proliferative vitreoretinopathy: results of additional and long-term follow-up. Silicone Study report 11.

Authors:  G W Abrams; S P Azen; B W McCuen; H W Flynn; M Y Lai; S J Ryan
Journal:  Arch Ophthalmol       Date:  1997-03

5.  Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.

Authors:  Taiji Sakamoto; Miho Miyazaki; Toshio Hisatomi; Takao Nakamura; Akifumi Ueno; Keiko Itaya; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-03-15       Impact factor: 3.117

6.  The classification of retinal detachment with proliferative vitreoretinopathy.

Authors: 
Journal:  Ophthalmology       Date:  1983-02       Impact factor: 12.079

7.  Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide.

Authors:  Koh-Hei Sonoda; Taiji Sakamoto; Hiroshi Enaida; Miho Miyazaki; Yoshihiro Noda; Takao Nakamura; Akifumi Ueno; Mitsunobu Yokoyama; Toshiaki Kubota; Tatsuro Ishibashi
Journal:  Ophthalmology       Date:  2004-02       Impact factor: 12.079

8.  Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.

Authors:  Wendy Tseng; Rafael T Cortez; Gema Ramirez; Sandra Stinnett; Glenn J Jaffe
Journal:  Am J Ophthalmol       Date:  2004-06       Impact factor: 5.258

9.  Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy.

Authors:  Claudio Furino; Tommaso Micelli Ferrari; Francesco Boscia; Nicola Cardascia; Nicola Recchimurzo; Carlo Sborgia
Journal:  Retina       Date:  2003-12       Impact factor: 4.256

10.  One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy.

Authors:  Keita Yamakiri; Taiji Sakamoto; Yoshihiro Noda; Masaaki Nakahara; Nobuchika Ogino; Toshiaki Kubota; Mitsunobu Yokoyama; Mariko Furukawa; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-04-23       Impact factor: 3.117

View more
  3 in total

1.  Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one.

Authors:  Marina V Tikhonovich; Aleksei K Erdiakov; Svetlana A Gavrilova
Journal:  Int Ophthalmol       Date:  2017-06-21       Impact factor: 2.031

2.  Adjunctive serial post-operative intravitreal methotrexate injections in the management of advanced proliferative vitreoretinopathy.

Authors:  José A Roca; Analí Yon-Mendoza; Nathaly Huamán; Lihteh Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-04-26       Impact factor: 3.117

Review 3.  Steroids as an adjunct for reducing the incidence of proliferative vitreoretinopathy after rhegmatogenous retinal detachment surgery: a systematic review and meta-analysis.

Authors:  Hui Shi; Tao Guo; Peng-Cheng Liu; Qian-Yi Wang; Ya-Ru Du; Qing-Yu Liu; Meng-Mei He; Jun-Ling Liu; Jing Yu
Journal:  Drug Des Devel Ther       Date:  2015-03-06       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.